tradingkey.logo

Becton Dickinson and Co

BDX
200.090USD
-0.800-0.40%
收盤 12/15, 16:00美東報價延遲15分鐘
57.11B總市值
34.30本益比TTM

Becton Dickinson and Co

200.090
-0.800-0.40%

關於 Becton Dickinson and Co 公司

Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. Its BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, advanced monitoring, and pharmaceutical systems. Its BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. Its BD Interventional segment provides vascular, urology, oncology and surgical specialty products.

Becton Dickinson and Co簡介

公司代碼BDX
公司名稱Becton Dickinson and Co
上市日期Oct 31, 2099
CEOPolen (Thomas E)
員工數量72000
證券類型Ordinary Share
年結日Oct 31
公司地址One Becton Drive
城市FRANKLIN LAKES
上市交易所NASDAQ OMX NASDAQ Basic NYSE
國家United States of America
郵編07417-1880
電話12018476800
網址https://www.bd.com/
公司代碼BDX
上市日期Oct 31, 2099
CEOPolen (Thomas E)

Becton Dickinson and Co公司高管

名稱
名稱/職務
職務
持股
持股變動
Mr. Richard (Rick) Byrd
Mr. Richard (Rick) Byrd
Executive Vice President, President - Interventional Segment
Executive Vice President, President - Interventional Segment
761.54K
+0.94%
Mr. Timothy M. (Tim) Ring
Mr. Timothy M. (Tim) Ring
Independent Director
Independent Director
59.87K
+1.58%
Ms. Shana Carol Neal
Ms. Shana Carol Neal
Chief People Officer, Executive Vice President
Chief People Officer, Executive Vice President
54.82K
+16.58%
Mr. Roland Goette
Mr. Roland Goette
Executive Vice President, President - EMEA
Executive Vice President, President - EMEA
17.21K
+21.15%
Mr. Michael Feld
Mr. Michael Feld
Executive Vice President, President - Life Sciences
Executive Vice President, President - Life Sciences
16.58K
-0.45%
Ms. Catherine M. (Cathy) Burzik
Ms. Catherine M. (Cathy) Burzik
Independent Director
Independent Director
14.81K
+6.70%
Mr. Antoine C. Ezell
Mr. Antoine C. Ezell
Executive Vice President, President, North America, Chief Marketing Officer
Executive Vice President, President, North America, Chief Marketing Officer
11.97K
+28.43%
Mr. Robert Andrew (Andy) Eckert
Mr. Robert Andrew (Andy) Eckert
Independent Director
Independent Director
9.14K
+11.33%
Ms. Michelle Quinn
Ms. Michelle Quinn
Executive Vice President, General Counsel
Executive Vice President, General Counsel
6.93K
+39.80%
Mr. Gregory J. Hayes
Mr. Gregory J. Hayes
Independent Director
Independent Director
6.05K
+659.55%
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Richard (Rick) Byrd
Mr. Richard (Rick) Byrd
Executive Vice President, President - Interventional Segment
Executive Vice President, President - Interventional Segment
761.54K
+0.94%
Mr. Timothy M. (Tim) Ring
Mr. Timothy M. (Tim) Ring
Independent Director
Independent Director
59.87K
+1.58%
Ms. Shana Carol Neal
Ms. Shana Carol Neal
Chief People Officer, Executive Vice President
Chief People Officer, Executive Vice President
54.82K
+16.58%
Mr. Roland Goette
Mr. Roland Goette
Executive Vice President, President - EMEA
Executive Vice President, President - EMEA
17.21K
+21.15%
Mr. Michael Feld
Mr. Michael Feld
Executive Vice President, President - Life Sciences
Executive Vice President, President - Life Sciences
16.58K
-0.45%
Ms. Catherine M. (Cathy) Burzik
Ms. Catherine M. (Cathy) Burzik
Independent Director
Independent Director
14.81K
+6.70%

收入明細

單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2021
FY2020
FY2019
業務USD
名稱
營收
佔比
Medication Delivery Solutions
1.13B
20.55%
Medication Management Solutions
888.00M
16.12%
Pharmaceutical Systems
629.00M
11.42%
Peripheral Intervention
512.00M
9.29%
Specimen Management
470.00M
8.53%
其他
1.88B
34.09%
地區USD
名稱
營收
佔比
United States
3.18B
57.72%
International
2.33B
42.26%
業務
地區
業務USD
名稱
營收
佔比
Medication Delivery Solutions
1.13B
20.55%
Medication Management Solutions
888.00M
16.12%
Pharmaceutical Systems
629.00M
11.42%
Peripheral Intervention
512.00M
9.29%
Specimen Management
470.00M
8.53%
其他
1.88B
34.09%

股東統計

更新時間: 11月15日 週六
更新時間: 11月15日 週六
持股股東
股東類型
持股股東
持股股東
佔比
The Vanguard Group, Inc.
11.32%
T. Rowe Price Investment Management, Inc.
5.69%
BlackRock Institutional Trust Company, N.A.
5.17%
State Street Investment Management (US)
4.86%
First Eagle Investment Management, L.L.C.
3.50%
其他
69.45%
持股股東
持股股東
佔比
The Vanguard Group, Inc.
11.32%
T. Rowe Price Investment Management, Inc.
5.69%
BlackRock Institutional Trust Company, N.A.
5.17%
State Street Investment Management (US)
4.86%
First Eagle Investment Management, L.L.C.
3.50%
其他
69.45%
股東類型
持股股東
佔比
Investment Advisor
48.66%
Investment Advisor/Hedge Fund
35.74%
Research Firm
2.91%
Pension Fund
2.39%
Bank and Trust
1.46%
Hedge Fund
1.42%
Sovereign Wealth Fund
1.36%
Individual Investor
0.60%
Insurance Company
0.32%
其他
5.13%

機構持股

更新時間: 12月8日 週一
更新時間: 12月8日 週一
報告期間
機構數
持股數
持股佔比
持股變動
2025Q4
2786
268.89M
98.17%
+69.96K
2025Q3
2887
268.83M
99.00%
+3.34M
2025Q2
2905
265.92M
96.81%
+120.40K
2025Q1
2872
266.25M
96.81%
-11.23M
2024Q4
2862
265.61M
95.72%
+1.13M
2024Q3
2775
265.14M
93.34%
+4.39M
2024Q2
2770
259.79M
92.17%
+1.30M
2024Q1
2779
258.85M
91.59%
-5.84M
2023Q4
2763
257.96M
92.19%
-5.24M
2023Q3
2735
263.83M
91.15%
+1.97M
查看更多

股東持股明細

名稱
持股數
佔比
持股變動
變動比例
公告日期
The Vanguard Group, Inc.
32.17M
11.22%
+4.30M
+15.41%
Jun 30, 2025
T. Rowe Price Investment Management, Inc.
16.18M
5.64%
+3.60M
+28.65%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
15.15M
5.29%
+360.45K
+2.44%
Jun 30, 2025
State Street Investment Management (US)
13.41M
4.68%
-579.46K
-4.14%
Jun 30, 2025
First Eagle Investment Management, L.L.C.
8.79M
3.07%
+3.27M
+59.18%
Jun 30, 2025
MFS Investment Management
7.69M
2.68%
+1.58M
+25.78%
Jun 30, 2025
Geode Capital Management, L.L.C.
6.72M
2.35%
+244.20K
+3.77%
Jun 30, 2025
ClearBridge Investments, LLC
3.80M
1.33%
+321.67K
+9.24%
Jun 30, 2025
查看更多

持股ETF

更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
iShares U.S. Medical Devices ETF
4.25%
FPA Global Equity ETF
3.12%
Cullen Enhanced Equity Income ETF
3.1%
American Century Focused Large Cap Value ETF
3.04%
iShares Large Cap Value Active ETF
2.72%
First Eagle Global Equity ETF
2.66%
Franklin ClearBridge Enhanced Income ETF
2.66%
T Rowe Price Capital Appreciation Equity ETF
2.65%
Brandes US Value ETF
2.26%
First Trust Indxx Medical Devices ETF
1.92%
查看更多
iShares U.S. Medical Devices ETF
佔比4.25%
FPA Global Equity ETF
佔比3.12%
Cullen Enhanced Equity Income ETF
佔比3.1%
American Century Focused Large Cap Value ETF
佔比3.04%
iShares Large Cap Value Active ETF
佔比2.72%
First Eagle Global Equity ETF
佔比2.66%
Franklin ClearBridge Enhanced Income ETF
佔比2.66%
T Rowe Price Capital Appreciation Equity ETF
佔比2.65%
Brandes US Value ETF
佔比2.26%
First Trust Indxx Medical Devices ETF
佔比1.92%

分紅派息

近5年累計派現 5.54B 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
Nov 06, 2025
BDX.NB Final Cash Dividend of gross USD 1.05 paid on Dec 31, 2025 going ex on Dec 08, 2025
Dec 08, 2025
Dec 31, 2025
Dec 08, 2025
Jul 22, 2025
BDX.NB Interim Cash Dividend of gross USD 1.04 paid on Sep 30, 2025 going ex on Sep 08, 2025
Sep 08, 2025
Sep 30, 2025
Sep 08, 2025
Apr 29, 2025
BDX.NB Interim Cash Dividend of gross USD 1.04 paid on Jun 30, 2025 going ex on Jun 09, 2025
Jun 09, 2025
Jun 30, 2025
Jun 09, 2025
Jan 28, 2025
BDX.NB Interim Cash Dividend of gross USD 1.04 paid on Mar 31, 2025 going ex on Mar 10, 2025
Mar 10, 2025
Mar 31, 2025
Mar 10, 2025
Nov 07, 2024
BDX.NB Final Cash Dividend of gross USD 1.04 paid on Dec 31, 2024 going ex on Dec 09, 2024
Dec 09, 2024
Dec 31, 2024
Dec 09, 2024
Jul 23, 2024
BDX.NB Interim Cash Dividend of gross USD 0.95 paid on Sep 30, 2024 going ex on Sep 09, 2024
Sep 09, 2024
Sep 30, 2024
Sep 09, 2024
Apr 30, 2024
BDX.NB Interim Cash Dividend of gross USD 0.95 paid on Jun 28, 2024 going ex on Jun 10, 2024
Jun 10, 2024
Jun 28, 2024
Jun 10, 2024
Jan 23, 2024
BDX.NB Interim Cash Dividend of gross USD 0.95 paid on Mar 29, 2024 going ex on Mar 07, 2024
Mar 08, 2024
Mar 29, 2024
Mar 07, 2024
Nov 09, 2023
BDX.NB Final Cash Dividend of gross USD 0.95 paid on Dec 29, 2023 going ex on Dec 07, 2023
Dec 08, 2023
Dec 29, 2023
Dec 07, 2023
Jul 25, 2023
BDX.NB Interim Cash Dividend of gross USD 0.91 paid on Sep 29, 2023 going ex on Sep 07, 2023
Sep 08, 2023
Sep 29, 2023
Sep 07, 2023
查看更多

拆合股

公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據

常見問題

Becton Dickinson and Co的前五大股東是誰?

Becton Dickinson and Co的前五大股東如下:
The Vanguard Group, Inc.
持有股份:32.17M
佔總股份比例:11.22%。
T. Rowe Price Investment Management, Inc.
持有股份:16.18M
佔總股份比例:5.64%。
BlackRock Institutional Trust Company, N.A.
持有股份:15.15M
佔總股份比例:5.29%。
State Street Investment Management (US)
持有股份:13.41M
佔總股份比例:4.68%。
First Eagle Investment Management, L.L.C.
持有股份:8.79M
佔總股份比例:3.07%。

Becton Dickinson and Co的前三大股東類型是什麼?

Becton Dickinson and Co 的前三大股東類型分別是:
The Vanguard Group, Inc.
T. Rowe Price Investment Management, Inc.
BlackRock Institutional Trust Company, N.A.

有多少機構持有Becton Dickinson and Co(BDX)的股份?

截至2025Q4,共有2786家機構持有Becton Dickinson and Co的股份,合計持有的股份價值約為268.89M,占公司總股份的98.17% 。與2025Q3相比,機構持股有所增加,增幅為-0.83%。

哪個業務部門對Becton Dickinson and Co的收入貢獻最大?

在FY2025Q3,Medication Delivery Solutions業務部門對Becton Dickinson and Co的收入貢獻最大,創收1.13B,占總收入的20.55% 。
KeyAI